Driving away Big Pharma is not NICE or clever:
Driving away Big Pharma is not NICE or clever
Drug companies are not villains, they are responsible for most medical breakthroughs. So why make life hard for them?
Driving away Big Pharma is not NICE or clever
Drug companies are not villains, they are responsible for most medical breakthroughs. So why make life hard for them?
NICE - new ACD for imatinib intolerantce:
The Leukaemia and Lymphoma Society, US, have produced another excellent webcast 'Current treatment Options in CML-Progress in Research' with the following speakers:
Michael J. Mauro, MD
K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate
B. Douglas Smith1, Yvette L. Kasamon1, Jeanne Kowalski1, Christopher Gocke1, Kathleen Murphy1, Carole B. Miller2, Elizabeth Garrett-Mayer3, Hua-Ling Tsai1, Lu Qin1, Christina Chia1, Barbara Biedrzycki1, Thomas C. Harding4, Guang Haun Tu4, Richard Jones1, Kristen Hege4 and Hyam I. Levitsky1
Spotlight Review
Leukemia (2010) 24, 6–12; doi:10.1038/leu.2009.193; published online 1 October 2009
Cord blood stem cell transplant - hopes lifted
Matching donors cannot always be found, despite extensive registries
A technique which may eventually remove the need for matched bone marrow transplants has been used in humans for the first time.
Cancer News Article
Danusertib, a Multi-Kinase Aurora Inhibitor, Promising for Treatment of CML Refractory to First- and Second-generation Kinase Inhibitors
Researchers involved in an international multicenter Phase I study have reported that danusertib (PHA-739358) produces responses in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) who have failed treatment with Gleevec® (imatinib), Sprycel® (dasatinib), and Tasigna® (nilotinib). The details of this study were presented at the 2009 meeting of the American Society of Hematology (ASH) in New Orleans in early December.[1]
Here is a direct link to the number 10 petition that Michele started.